inhaled nitric oxide is one of 199 small molecule programs targeting Pulmonary Hypertension. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
120 competitors in Chronic Obstructive Pulmonary Disease
EXDENSUR
Lunsekimig
inhaled nitric oxide
Tozorakimab
CM310
Astegolimab
Titrated Oxygen
HSK39004
RLS-0071
Calciferol
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details